ProscaVax Reduced Tumor Growth in 70% of Prostate Cancer Patients, Early-stage Study Shows
News
OncBioMune‘s investigational cancer vaccine ProscaVax reduced tumor growth in 70% of prostate cancer patients included in a Phase 1a study. The immunotherapy candidate consists of a combination of the PSA protein ... Read more